

P&T Motion History
Asthma Controller / COPD Drugs

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
beclomethasone [A] budesonide [A] ciclesonide [A] flunisolide [A] fluticasone furoate [A] fluticasone propionate [A] mometasone DPI pwdr [A] mometasone MDI aerosol [A]	<p>Inhaled Corticosteroids</p> <p>After considering the evidence of safety, efficacy and special populations for the treatment of Asthma, I move that</p> <p>beclomethasone [A] budesonide [A] ciclesonide [A] flunisolide [A] fluticasone furoate [A] fluticasone propionate [A] mometasone MDI aerosol [A] mometasone DPI powder [A]</p> <p>are safe and efficacious for the treatment of their approved indications. Inhaled corticosteroids can be subject to therapeutic interchange in the Washington preferred drug list.</p> <p>All delivery systems and indications will be included for all drugs.</p> <p>Motion: MacKay 2nd: Barkett</p>	June 26, 2024	N/A	Yes	Passed unanimous

**P&T Motion History
Asthma Controller / COPD Drugs**

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
arformoterol [C] formoterol neb soln [C] formoterol DPI pwdr [A, C] indacaterol [C] olodaterol [C] salmeterol [A, C]	<p>Long-Acting Beta Agonists</p> <p>After considering the evidence of safety, efficacy and special populations for the treatment of Asthma and COPD, I move that</p> <p>arformoterol [C] formoterol nebulizer sol [C] formoterol pwdr [A,C] indacaterol [C] olodaterol [C] salmeterol [A, C]</p> <p>are safe and efficacious for the treatment of COPD and when used in the combination with inhaled corticosteroids for the treatment of asthma. Long-Acting Beta Agonists can be subject to therapeutic interchange in the Washington preferred drug list if the preferred drug is approved for the condition being treated.</p> <p>All delivery systems and indications will be included for all drugs.</p> <p>Motion: Flynn 2nd: Mackay</p>	June 26, 2024	N/A	No	Passed unanimous

Bold = new this update, Grey = not reviewed, cannot be included in motion
 [A] = Approved for Asthma, [C] = Approved for COPD
 7/2/2024

**P&T Motion History
Asthma Controller / COPD Drugs**

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
montelukast [A] zafirlukast [A] zileuton [A]	<p>Leukotriene Modifiers</p> <p>After considering the evidence of safety, efficacy and special populations for the treatment of asthma, I move that montelukast, zafirlukast, and zileuton are efficacious. Montelukast and zafirlukast may be associated with a lower incidence of hepatic toxicity than zileuton. Zileuton shall not be a preferred drug on the Washington Preferred drug list. Leukotriene modifiers can be subject to therapeutic interchange on the Washington Preferred Drug List for the indication of asthma.</p> <p>Motion: Barkett 2nd: Weiland</p>	June 26, 2024	N/A	Yes	Passed unanimous

**P&T Motion History
Asthma Controller / COPD Drugs**

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
<p><u>ICS/LABA</u> budesonide/formoterol [A, C] fluticasone propionate/salmeterol DPI [A, C] fluticasone propionate/salmeterol MDI [A] fluticasone furoate/vilanterol [A,C] mometasone furoate/formoterol furoate [A]</p>	<p>ICS/LABA Combinations After considering the evidence of safety, efficacy and special populations for the treatment of Asthma and COPD, I move that fluticasone propionate/salmeterol DPI and MDI [A, C], budesonide/ formoterol [A, C], fluticasone furoate/vilanterol [A, C] and mometasone furoate/formoterol [A] are safe and efficacious for the treatment of their approved indications. At least one formulation of ICS/formoterol will be included as a preferred drug for Asthma on the Washington PDL. Formoterol/ICS for Asthma may only be interchanged with another formoterol/ICS product. Long-Acting Beta Agonist Combination with ICS products can be subject to therapeutic interchange in the Washington preferred drug list if the preferred drug is approved for the condition being treated.</p> <p>All delivery systems and indications will be included for all drugs.</p> <p>Motion: Flynn</p>	<p>June 26, 2024</p>	<p>N/A</p>	<p>No</p>	<p>Passed unanimous</p>

Bold = new this update, Grey = not reviewed, cannot be included in motion
[A] = Approved for Asthma, [C] = Approved for COPD
7/2/2024

P&T Motion History
Asthma Controller / COPD Drugs

	2 nd : Hudson				
--	--------------------------	--	--	--	--

Bold = new this update, Grey = not reviewed, cannot be included in motion
[A] = Approved for Asthma, [C] = Approved for COPD
7/2/2024

**P&T Motion History
Asthma Controller / COPD Drugs**

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
<p>LAMA/LABA indacaterol/glycopyrrolate [C] olodaterol/tiotropium [C] umeclidinium/vilanterol [C] formoterol/glycopyrrolate [C] formoterol/aclidinium [C]</p>	<p>LAMA/LABA Combinations After considering the evidence of safety, efficacy and special populations for the treatment of Asthma and COPD, I move that indacaterol/glycopyrrolate [C], olodaterol/tiotropium [C], and umeclidinium/vilanterol [C] are safe and efficacious for the treatment of their approved indications. Long-Acting Beta Agonist Combination with LAMA products can be subject to therapeutic interchange in the Washington preferred drug list if the preferred drug is approved for the condition being treated.</p> <p>All delivery systems and indications will be included for all drugs.</p> <p>Motion: Beste 2nd: Barkett</p>	<p>June 26, 2024</p>	<p>N/A</p>	<p>No</p>	<p>Passed unanimous</p>

P&T Motion History
Asthma Controller / COPD Drugs

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
roflumilast [C]	<p>Phosphodiesterase-4 Inhibitor After considering the evidence of safety, efficacy and special populations for the treatment of COPD, I move that roflumilast [C] is safe and efficacious for the treatment of COPD. Phosphodiesterase-4 inhibitors can be subject to therapeutic interchange in the Washington preferred drug list.</p> <p>All delivery systems and indications will be included for all drugs.</p> <p>Motion: Hudson 2nd: MacKay</p>	June 26, 2024	N/A	No	Passed unanimous

**P&T Motion History
Asthma Controller / COPD Drugs**

Drugs Reviewed	Motion	Date Reviewed	Scan Accepted as Adequate	Reiteration of Prior Motion	Decision
aclidinium [C] glycopyrrolate [C] tiotropium DPI pwdr [C] tiotropium SMI mist [A, C] umeclidinium [C]	<p>Long-acting Muscarinic Antagonists (LAMA)</p> <p>After considering the evidence of safety, efficacy and special populations for the treatment of Asthma and COPD, I move that aclidinium [C], glycopyrrolate [C], tiotropium DPI powder [C], tiotropium SMI mist [A, C] and umeclidinium [C] are safe and efficacious for the treatment of their approved indications. LAMAs can be subject to therapeutic interchange in the Washington preferred drug list.</p> <p>All delivery systems and indications will be included for all drugs.</p> <p>Motion: Barkett 2nd: Flynn</p>	June 26, 2024	N/A	No	Passed unanimous

**P&T Motion History
Asthma Controller / COPD Drugs**

Drugs reviewed	Motion	Date reviewed	Surveillance accepted as adequate	Reiteration of prior motion	Decision
<p><u>ICS/LABA/LAMA</u> budesonide/glycopyrrolate/formoterol [C] fluticasone/umeclidinium/vilanterol [A, C] beclomethasone/glycopyrronium/formoterol [A, C]</p>	<p>ICS/LABA/LAMA Combinations After considering the evidence of safety, efficacy and special populations for the treatment of Asthma and COPD, I move that budesonide/ glycopyrrolate/ formoterol furoate [C] and fluticasone/umeclidinium/vilanterol [A, C] are safe and efficacious for the treatment of their approved indications. Long-acting Beta Agonist Combination with ICS and LAMA products can be subject to therapeutic interchange in the Washington preferred drug list if the preferred drug is approved for the condition being treated.</p> <p>All delivery systems and indications will be included for all drugs.</p> <p>Motion: Beste 2nd: Weiland</p>	<p>June 26, 2024</p>	<p>N/A</p>	<p>No</p>	<p>Passed unanimous</p>